MB-SBPH@EC2602A(15494.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
MB-SBPH@EC2602A
15494.HK
News
View More

Sino Biopharma CEO on China's Rapid Clinical Trial Growth

Sino Biopharmaceutical CEO Eric Tse discusses the "survival" necessity of China's rapid clinical trial growth and his open-ended approach to deals in 2026. He speaks to Bloomberg TV's Haslinda Amin on the sidelines of the 2026 World Economic Forum in Davos, Switzerland.Bloomberg videos, provided by MT Newswires

marketscreener·
SZ
159929
+0.36%
SZ
159837
+0.77%
SZ
159859
+1.98%
marketscreener·
SZ
159929
+0.36%
SZ
159837
+0.77%
SZ
159859
+1.98%

Top 5 HK Stock Gainers/Losers (>100B) (1.19)

CHINA EAST AIR(00670) rose 9.2%, with a trading turnover 216.5 Million HKD, and a year-to-date rose 6.9%. CTG DUTY-FREE(01880) rose 6.65%, with a trading turnover 350.2 Million HKD, and a year-to-date rose 10.8%. MINIMAX-WP(00100) fell 13.7%, with a trading turnover 649.0 Million HKD, and a year-to-date rose 129.1%. BILIBILI-W(09626) fell 6.85%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 25.6%.

Top Gainers & Losers·
HK
00670
+0.18%
HK
01880
+2.46%
HK
03986
-5.57%
Top Gainers & Losers·
HK
00670
+0.18%
HK
01880
+2.46%
HK
03986
-5.57%

In "Major Banks," China International Capital Corporation (CICC) stated that the acquisition of SINO BIOPHARM could enhance the layout in the weight loss metabolism field, maintaining a target price of 8.9 yuan

CICC released a research report stating that SINO BIOPHARM acquired Hegia Biotech for RMB 1.2 billion, focusing on weight loss metabolism, cardiovascular, and nervous system fields. This acquisition will help SINO BIOPHARM build an innovative pipeline for cardiovascular treatments to meet clinical needs in the chronic disease sector. CICC maintains its net profit forecasts for 2025 and 2026, and introduces a forecast for 2027, with a target price of HKD 8.9 and a rating of "outperform the industry."

AASTOCKS·
HK
01177
-2.11%
AASTOCKS·
HK
01177
-2.11%

Sino Biopharm To Remain Active in M&A, Says Chair

Sino Biopharmaceutical Chairwoman Theresa Tse says her company is open to acquiring more biotech companies in China after announcing a new buyout. She also tells "Bloomberg: The China Show" that the company is looking for partnerships with bigger multinational firms.Bloomberg videos, provided by MT Newswires

marketscreener·
HK
01177
-2.11%
marketscreener·
HK
01177
-2.11%

Sino Biopharm Shares Jump After Plan to Acquire Hygieia

Sino Biopharmaceutical's shares surged by 5.5% after announcing plans to acquire Hangzhou Hygieia Biomedical for up to 1.2 billion yuan (US$172 million). The acquisition aims to enhance Sino Biopharm's innovation in chronic disease treatments, positioning it as a new growth engine. Analysts view the deal positively, highlighting Sino Biopharm's commitment to expanding its research pipeline. The Chinese healthcare sector has seen significant innovation, attracting interest from global pharmaceutical companies, with the Hang Seng Biotech Index rising over 17% this year.

marketscreener·
HK
01177
-2.11%
marketscreener·
HK
01177
-2.11%
Posts
View More
© 2026 Longbridge｜Disclaimer